Topic:Sucralfate
Sucralfate is a medication used in horses primarily for the treatment and management of gastrointestinal conditions, such as gastric ulcers. It acts as a local protectant by forming a viscous, adhesive substance that adheres to the ulcer site, creating a barrier against gastric acid and pepsin. This protective action aids in the healing of ulcers by reducing further irritation and allowing tissue repair. Sucralfate is often administered orally and may be used in conjunction with other treatments, such as proton pump inhibitors or H2 antagonists, to manage equine gastric ulcer syndrome (EGUS) more effectively. This page compiles peer-reviewed research studies and scholarly articles that explore the pharmacology, therapeutic applications, and clinical outcomes associated with sucralfate use in equine medicine.
Effect of omeprazole and sucralfate on gastrointestinal injury in a fasting/NSAID model. Equine gastric ulcer syndrome (EGUS) is a common and significant cause of morbidity in horses, with a range of clinical signs, including inappetence, colic and poor performance. Hospitalised horses are exposed to factors that may induce EGUS, including fasting and nonsteroidal anti-inflammatory drug (NSAID) administration, and may be at risk for development of squamous (ESGD) and glandular gastric disease (EGGD). Prophylactic anti-ulcer medication is often prescribed for these patients, but drug selection is complicated by different aetiology and response to treatment of ESGD and EGGD. Objecti...
Misoprostol is superior to combined omeprazole-sucralfate for the treatment of equine gastric glandular disease. Previous studies have demonstrated a poor response to healing of gastric glandular lesions with oral omeprazole and other medications. Objective: To evaluate the efficacy of two novel treatments (misoprostol [M] and combined omeprazole-sucralfate [OS]) in horses for gastric glandular disease. Methods: Prospective, clinical study. Methods: Sixty-three sports horses with grade >1/4 glandular disease were identified by gastroscopy. Horses received either 5 μg/kg of misoprostol per os BID 1 h prior to feeding or a combination of 4 mg/kg enteric coated omeprazole per os SID and 12 mg/kg sucral...
Effect of sucralfate on total carbon dioxide concentration in horses subjected to a simulated race test. The purpose of this study was to test the hypothesis that sucralfate, a gastric ulcer medication, would alter plasma concentrations of total carbon dioxide (tCO2), lactate (LA), sodium (Na+), potassium (K+), chloride (Cl-) and total protein (TP), as well as calculated plasma strong ion difference (SID) and packed cell volume (PCV) in horses subjected to a simulated race test (SRT). Six unfit Standardbred mares (approximately 520 kg, 9-18 years) were used in a randomized crossover design with the investigators blinded to the treatment given. The horses were assigned to either a control (40-50 m...
Equine gastric ulcer syndrome in adult horses: a review. In recent years, gastric ulceration has been recognised as a common, possibly performance-limiting disease of adult horses. Here, we aim to provide the reader with a useful review of recent literature covering all aspects of equine gastric ulcer syndrome (EGUS) in adult horses. The anatomy and physiology of the stomach, with particular reference to secretion of acid and mucosal protective mechanisms, are reviewed, as are the differing theories relating to the aetiopathogenesis of gastric ulceration. We also explore the possible influence of various management factors on development of the dise...
Effect of sucralfate on healing of subclinical gastric ulcers in foals. The effect of sucralfate on healing of subclinical gastric ulcers and gastric inflammation was investigated in twelve 6- to 7-month-old foals. Foals with endoscopically evident gastric lesions on day 0 were assigned to 1 of 2 groups, on the basis of mucosal inflammation and number and severity of ulcers, to create groups of foals with approximately equal severity of lesions. None of these foals had clinical signs of gastroduodenal ulcer disease. Groups were assigned to receive sucralfate (22.0 mg/kg of body weight) or corn syrup for 14 days, PO, every 8 hours. On day 15, gastroscopic examinati...
The protective effects of sucralfate and ranitidine in foals experimentally intoxicated with phenylbutazone. The effects of sucralfate and ranitidine on the gastrointestinal manifestations of phenylbutazone (PBZ) toxicity in horse foals were determined by complete blood count, serum chemistry profile, and gross and histological necropsy examinations. Twenty-eight, three to four month old Belgian-cross foals were randomly assigned to one of four groups. Phenylbutazone was administered at a dosage of 10 mg/kg of bodyweight (BW) per day, intravenously (IV), in equally divided doses to three of the groups. In addition to PBZ, ranitidine was administered at 2 mg/kg BW, IV, twice daily, to one group of sev...
Gastroduodenal ulceration in foals. Gastroduodenal ulceration is becoming recognised as an important disease in foals during the first few months of life. Aetiopathogenesis is presumed to be similar to peptic disease in humans associated with back diffusion of hydrogen ions into the mucosa. Many factors have been incriminated as predisposing foals to ulceration but few have been proven. To date, use of non-steroidal anti-inflammatory agents has been the only documented cause of gastroduodenal ulceration in foals. The clustering of affected foals on certain farms suggests an infectious aetiology but attempts to identify a causati...